Star Imaging & Path Lab IPO
LiveAlready have an account? Apply now
Schedule of Star Imaging & Path Lab
| Issue open date | 08 Aug 2025 |
| Issue close date | 12 Aug 2025 |
| UPI mandate deadline | 12 Aug 2025 (5 PM) |
| Allotment finalization | 13 Aug 2025 |
| Refund initiation | 14 Aug 2025 |
| Share credit | 14 Aug 2025 |
| Listing date | 18 Aug 2025 |
| Mandate end date | 28 Aug 2025 |
| Lock-in end date for anchor investors (50%) | 12 Sep 2025 |
| Lock-in end date for anchor investors (remaining) | 11 Nov 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Star Imaging & Path Lab
Incorporated in 2004, Star Imaging and Path Lab is a healthcare diagnostics company providing a broad spectrum of medical testing services across multiple regions. The company operates with a dual focus on imaging and laboratory diagnostics, delivering comprehensive diagnostic solutions to both individual patients and healthcare institutions.
Financials of Star Imaging & Path Lab
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹69.47 crores |
| Fresh Issue | ₹55.67 crores |
| Offer for Sale | ₹13.80 crores |
Utilisation of proceeds
| Purpose | INR crores (%) |
| To meet working capital requirements | 25 |
| Repayment/prepayment of certain borrowings | 12 |
| Funding the capital expenditure towards purchase of refurbished medical equipment in running facilities | 5.14 |
| General corporate purposes |
Strengths
- A comprehensive, integrated suite of diagnostic services, including pathology, radiology, cardiology, and neurology, all under one roof
- Operates across B2C, B2B, and B2G segments, providing a broad revenue base and market reach
- With a strong network and strategic expansion, Star Imaging ensures broad access to diagnostic services
- Experienced leadership with a strong track record in the diagnostic healthcare industry
- Continuous investment in advanced technology and strategic PPP engagement drive significant operational efficiencies
Risks
- Outstanding legal proceedings involving the company, directors, and promoters may impact cash flows and operations
- High reliance on Delhi & UP, makes the business vulnerable to regional disruptions
- Revenue concentration in pathology and radiology increases exposure to sector downturns
- Reliance on third-party vendors and institutional customers without long-term contracts
- Recent negative cash flows, high competition, and potential loss of leased premises could adversely affect the business
Subscription Figures for Star Imaging & Path Lab
As per media reports (Link), the Grey Market Premium (GMP) of Star Imaging & Path Lab is reported at ₹0 over the IPO price. This metric is not reliable, and to track IPO interest, it is better to check subscription numbers published by exchanges, which are considered more reliable indicators.
Subscription numbers as of 5:00 PM on August 08, 2025:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 8.71 | 0 | 0.00x |
| NII | 6.57 | 0.86 | 0.13x |
| Retail | 15.28 | 0.80 | 0.05x |
| Employees | 0.52 | 0 | 0.00x |
| Total | 31.08 | 1.66 | 0.05x |